State pharmaceutical firm Kimia Farma (KAEF) suffered loss of Rp1.82 trillion in 2023, widened from Rp126 billion loss only in 2022, due to higher cost and expenses. Worse, the government as majority shareholder, detected financial engineering carried out by the company’s subsidiary. To subscribe please click here
